Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in Participants With Advanced KRAS- Mutant Solid Tumours.

NCT07148128 is registered in ClinicalTrials.gov with Auricula Biosciences Inc. as lead sponsor.

NCT NCT07148128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07148128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in Participants With Advanced KRAS- Mutant Solid Tumours.
Lead sponsor
Auricula Biosciences Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 28, 2025
Completion date
January 31, 2028
Enrollment
110 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic kras-mutant tumor, advanced or metastatic kras-mutant tumor in colorectal cancer, advanced or metastatic kras-mutant tumor in non small cell lung cancer, advanced or metastatic kras-mutant tumor in pancreatic adenocarcinoma, advanced solid tumors